Science and technology in Israel

Ituran Location and Control Ltd. Announces Execution of Rule 10b-15 and Rule 10b-18 for Share Repurchase Program

Retrieved on: 
Wednesday, August 4, 2021
Articles, Economy of Israel, Global Positioning System, Science and technology in Israel, Ituran, Economy, Business incubators, Tel Aviv, Startup company, Share repurchase

Share repurchases, if any, will be funded by the wholly owned subsidiary with available cash.

Key Points: 
  • Share repurchases, if any, will be funded by the wholly owned subsidiary with available cash.
  • Certain statements in this press release are "forward-looking statements" within the meaning of the Securities Act of 1933, as amended.
  • Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology.
  • Established in 1995, Ituran has approximately 3,000 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.

Ituran Location And Control Ltd. Schedules Second Quarter 2021 Results Release And Conference Call For Monday, August 23, 2021

Retrieved on: 
Monday, August 2, 2021
Articles, Western Asia, Asia, Economy of Israel, Global Positioning System, Science and technology in Israel, Ituran, Azour, Israel

AZOUR, Israel, Aug. 2, 2021 /PRNewswire/ --Ituran Location and Control Ltd. (NASDAQ: ITRN), announced that it will be releasing its second quarter 2021 results on Monday, August 23, 2021.

Key Points: 
  • AZOUR, Israel, Aug. 2, 2021 /PRNewswire/ --Ituran Location and Control Ltd. (NASDAQ: ITRN), announced that it will be releasing its second quarter 2021 results on Monday, August 23, 2021.
  • The Company will also be hosting a conference that day at 9:00 am Eastern Time.
  • On the call, management will review and discuss the results, and will be available to answer investor questions.
  • Established in 1995, Ituran has approximately 3,000 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.

Taro Provides Results for Quarter Ended June 30, 2021

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, FDA, Pharmaceutical, Health, Plants, Food and drink, Agriculture, Science and technology in Israel, Taro Pharmaceuticals, Taro, New York Stock Exchange

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2021.
  • Quarter ended June 30, 2021 Highlights - compared to Quarter ended June 30, 2020
    Net sales increased $29.5 million, or 25.1%, to $147.1 million.
  • Foreign Exchange expense of $0.3 million compared to income of $0.2 million in the comparable quarter an unfavorable impact of $0.5 million.
  • On June 17, 2021, Taro filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended March 31, 2021.

Catalent Launches New OptiDose® Design Solution to Help Create Differentiated Treatments that are Successful for Innovators, Patients and Health Care Professionals

Retrieved on: 
Monday, July 26, 2021
Life sciences, Health sciences, Articles, Design, Product development, Catalent, Pharmaceutics, Systems engineering, Dose

Catalent's OptiDose Design Solution, led by Catalent's scientific advisors, uses a design approach that combines data-driven scientific tools with Catalent's extensive development expertise.

Key Points: 
  • Catalent's OptiDose Design Solution, led by Catalent's scientific advisors, uses a design approach that combines data-driven scientific tools with Catalent's extensive development expertise.
  • Integrating pharmaceutics, and dose form design target patient characteristics, OptiDose Design Solution will help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.
  • At the CRS meeting, Lisa Caralli, Director of Science and Technology at Catalent, will discuss the methodology of the OptiDose Design Solution, including how key product and patient factors are evaluated.
  • Ms. Caralli's presentation, titled "Strategies to Optimize the Dose Design Process to Create Better Treatments", will use case studies to demonstrate how the correct guidance, at the optimum time, can help drug developers create better treatments.

Taro to Announce First Quarter Results on July 27, 2021

Retrieved on: 
Wednesday, July 21, 2021
Health, Pharmaceutical, Science and technology in Israel, Taro Pharmaceuticals, Pharmaceutical industry, Health care, Life sciences

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021.
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit the Companys website at www.taro.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210720006288/en/

Taro Announces Resignation of Chief Financial Officer

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, General Health, Pharmaceutical, Health, Science and technology in Israel, Taro Pharmaceuticals, Health sciences, Pharmaceutical industry, Pharmaceutical sciences, Health care

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.
  • The Company has initiated a search for a successor as Chief Financial Officer.
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit the Companys website at www.taro.com .

PixCell Medical Appoints Armin Schon as New Chief Commercial Officer to Foster Continued HemoScreen™ Growth

Retrieved on: 
Thursday, July 15, 2021
Economy of Israel, Science and technology in Israel, Yokneam Illit, Yokneam, Israel, Archaeological sites

YOKNEAM ILLIT, Israel, July 15, 2021 /PRNewswire/ -- PixCell Medical , innovator of rapid diagnostic solutions at the point-of-care, announced today that Armin Schon, Ph.D., has been appointed chief commercial officer, effective immediately.

Key Points: 
  • YOKNEAM ILLIT, Israel, July 15, 2021 /PRNewswire/ -- PixCell Medical , innovator of rapid diagnostic solutions at the point-of-care, announced today that Armin Schon, Ph.D., has been appointed chief commercial officer, effective immediately.
  • Schon will oversee PixCell's global commercial partnerships, all sales and marketing activities and distribution of the company's proprietary hematology analyzer, HemoScreen.
  • "As a member of PixCell's board, I helped the company progress to the commercial product we now know as HemoScreen.
  • Schon brings more than 20 years of multidisciplinary experience in strategy and business development for global science-based industries and medical device companies.

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021

Retrieved on: 
Friday, June 18, 2021
Pharmaceutical, Professional services, Health, Finance, Health sciences, Science and technology in Israel, Taro Pharmaceuticals, Pharmaceutical industry, Health care, Health

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit Taros website at www.taro.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210618005039/en/

Ituran's Mobility Investment Bringg Completes $100 Million Series-E Investment Round

Retrieved on: 
Wednesday, June 16, 2021
Articles, Economy of Israel, Global Positioning System, Science and technology in Israel, Ituran, Unicorn, Science and technology, Geography

AZOUR, Israel, June 16, 2021 /PRNewswire/ -- Ituran Location and Control Ltd. (NASDAQ: ITRN), today announced that its successful early-stage mobility technology holding, Bringg, completed a series-E investment round of $100 million.

Key Points: 
  • AZOUR, Israel, June 16, 2021 /PRNewswire/ -- Ituran Location and Control Ltd. (NASDAQ: ITRN), today announced that its successful early-stage mobility technology holding, Bringg, completed a series-E investment round of $100 million.
  • The round is being led by Insight Capital, a new investor, and included participation from several of its existing investors.
  • The investment sets Bringg's valuation at $1 billion, making it the first and only unicorn in last-mile delivery and fulfillment cloud technology.
  • Our investment in Bringg is a successful element of this strategy and Bringg has shown significant progress especially in the past year, with fast growing sales to top-tier global companies.

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Infectious diseases, Clinical medicine, Kamada, Rehovot, Science and technology in Israel, Neglected tropical diseases, Tropical diseases, Rabies

"As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.

Key Points: 
  • "As the U.S. market's first and only human rabies immune globulin to be studied in children, KEDRAB is an excellent example of that dedication.
  • Today's news will provide added peace of mind for physicians who choose KEDRAB in treating children who have possibly been exposed to rabies.
  • We are especially proud of our partnership with Kamada, which has resulted in this significant step forward in global health."
  • "Kamada is excited to have a HRIGthat can treat peopleof all ages in the U.S. with the FDA-approved label expansion for KEDRAB," said Amir London, Chief Executive Officer of Kamada.